The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis PDF Print E-mail
Saturday, 16 June 2012 03:43
Marta Baleva and Krasimir Nikolov
Received 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011

Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in Scleroderma is progressive development of fibrous tissue and obliteration of the microvasculature. Currently, there are no medical products for the treatment of Scleroderma that provide both sufficient immunosuppression and low-risk side safety profile with negligible side effects.

There are a large number of experimental data showing that intravenous immunoglobulin (IVIG) has multiple clinical and morphological effects. On the other hand, some authors report good effect of intravenous immune globulins in patients with Scleroderma. The less frequent side effects of IVIG in doses below or equal to 2 g/kg/month divided in 5 consecutive days make IVIG a promising treatment of choice in Scleroderma.

Continue reading the full review article, by downloading it from the link provided below.

 
More articles :

» Biomarkers Predict Lung Decline in Systemic Sclerosis

Predicting risk of pulmonary fibrosis and pulmonary hypertension is an urgent priority in systemic sclerosis. Lung function often declines rapidly in the first years after diagnosis, and interstitial lung disease (ILD), although highly variable in...

» Facing Life's Challenges

At 57 years of age Anne Wersching doesn’t have a single wrinkle on her face.Sitting in her lounge room in Bayswater North, Ms Wersching looks well, save for a few red marks on her cheeks.But Ms Wersching has a little-known disease called...

» Adult Stem Cells Are Helping Scleroderma Patients

Dr. Richard Burt and colleagues at Northwestern University have just published a new study in that provides more evidence for the success of adult stem cell transplant in treating System Sclerosis ().Ten patients were treated with their own adult...

» Preterm Delivery a Risk in Systemic Sclerosis

Many women with systemic sclerosis can have successful pregnancies, but the rates of preterm birth, low birth weight, and intrauterine growth restriction are approximately twice as high in these women compared to the general population of pregnant...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...

» The Heart In Scleroderma

Just as can affect multiple organ systems, the cardiac manifestations of the disease are diverse. Although only relatively recently recognized, the heart is a major organ involved in Scleroderma and the presence of cardiac involvement generally...